Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Horng-Yih
HY
Ou
Division of Endocrinology, Metabolism and Genetics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.
Rudruidee
R
Karnchanasorn
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, and Graduate Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Lee-Ming
LM
Chuang
Department of Diabetes, Endocrinology, and Metabolism, City of Hope, Duarte, CA, and Division of Endocrinology and Metabolism, Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA kchiu@coh.org.
Ken C
KC
Chiu
D000068896:Canagliflozin / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male
D007004:Hypoglycemic Agents; D000068896:Canagliflozin